Cancer Deaths Keep Falling as New Treatments, Diabetes Links, and Vitamin C Data Reshape Oncology

Cancer remains one of the leading threats to healthy aging and longevity, making this week's oncology roundup highly relevant for anyone tracking healthspan science. The overarching theme is cautious optimism: mortality is falling even as incidence climbs, and several emerging interventions offer new hope.

The CDC confirmed that U.S. cancer deaths declined from 2019 to 2023, with reduced lung cancer mortality as the primary driver. This trend reflects decades of tobacco control, earlier detection, and improving therapies. However, rising incidence rates signal that prevention remains an unfinished challenge, particularly as obesity and metabolic disease spread.

One of the most actionable findings is the link between type 2 diabetes and cancer risk. Data to be presented at the European Association for the Study of Diabetes meeting show that people with type 2 diabetes have approximately double the cancer risk compared with those without the condition. This underscores the critical importance of blood sugar management not just for cardiovascular or kidney health, but for cancer prevention across the lifespan.

On the treatment front, the combination of teclistamab plus daratumumab in relapsed or refractory multiple myeloma produced remarkable survival outcomes, with up to 87% of treated patients expected to live as long as an age-matched healthy population. The FDA also approved belzutifan plus lenvatinib for advanced renal cell carcinoma. Meanwhile, Vitamin C supplements showed preliminary evidence of reducing the risk of myeloid malignancies in patients with precancerous blood disorders, a finding with potential implications for high-risk older adults.

For cancer survivors, a longitudinal study found that physical activity, particularly walking, significantly reduced fatigue in colorectal cancer patients — reinforcing exercise as a cornerstone of recovery and quality of life. Caveats include that several findings are preliminary or drawn from conference presentations rather than peer-reviewed publications.